To decipher the mechanism mediating the in vivo anti-cancer activity of CBL0137, we first confirmed down-regulation of Myc mRNA in vivo by RT-qPCR in 4T1.2 tumors collected 7 days after a single CBL0137 treatment (Fig. 2E). This evidence concerns the gene MYC and cancer.